लोड हो रहा है...
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has represented the standard of care for advanced HCC for almost 10 years, offering a survival benefit when compared to pla...
में बचाया:
| में प्रकाशित: | J Hepatocell Carcinoma |
|---|---|
| मुख्य लेखकों: | , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Dove
2021
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260177/ https://ncbi.nlm.nih.gov/pubmed/34239844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S285726 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|